Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

Chronic heart failure (CHF) is a challenging burden on public health. Therapeutic strategies for CHF have developed rapidly in the past decades from conventional medical therapy, which mainly includes administration of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chun-Song Hu, Qing-Hua Wu, Da-Yi Hu, Tengiz Tkebuchava
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2019
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/02fb3e512c8c4901bce4e4f36630c152
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:02fb3e512c8c4901bce4e4f36630c152
record_format	dspace
spelling	oai:doaj.org-article:02fb3e512c8c4901bce4e4f36630c1522021-12-02T12:05:18ZTreatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come2095-882X10.1016/j.cdtm.2018.08.005https://doaj.org/article/02fb3e512c8c4901bce4e4f36630c1522019-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18300379https://doaj.org/toc/2095-882XChronic heart failure (CHF) is a challenging burden on public health. Therapeutic strategies for CHF have developed rapidly in the past decades from conventional medical therapy, which mainly includes administration of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists, to biomedical engineering methods, which include interventional engineering, such as percutaneous balloon mitral valvotomy, percutaneous coronary intervention, catheter ablation, biventricular pacing or cardiac resynchronization therapy (CRT) and CRT-defibrillator use, and implantable cardioverter defibrillator use; mechanical engineering, such as left ventricular assistant device use, internal artery balloon counterpulsation, cardiac support device use, and total artificial heart implantation; surgical engineering, such as coronary artery bypass graft, valve replacement or repair of rheumatic or congenital heart diseases, and heart transplantation (HT); regenerate engineering, which includes gene therapy, stem cell transplantation, and tissue engineering; and rehabilitating engineering, which includes exercise training, low-salt diet, nursing, psychological interventions, health education, and external counterpulsation/enhanced external counterpulsation in the outpatient department. These biomedical engineering therapies have greatly improved the symptoms of CHF and life expectancy. To date, pharmacotherapy, which is based on evidence-based medicine, large-scale, multi-center, randomized controlled clinical trials, is still a major treatment option for CHF; the current interventional and mechanical device engineering treatment for advanced CHF is not enough owing to its individual status. In place of HT or the use of a total artificial heart, stem cell technology and gene therapy in regenerate engineering for CHF are very promising. However, each therapy has its advantages and disadvantages, and it is currently possible to select better therapeutic strategies for patients with CHF according to cost-efficacy analyses of these therapies. Taken together, we think that a new era of biomedical engineering for CHF has begun. Keywords: Chronic heart failure, Biomedical engineering, TreatmentChun-Song HuQing-Hua WuDa-Yi HuTengiz TkebuchavaKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 2, Pp 75-88 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Chun-Song Hu Qing-Hua Wu Da-Yi Hu Tengiz Tkebuchava Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
description	Chronic heart failure (CHF) is a challenging burden on public health. Therapeutic strategies for CHF have developed rapidly in the past decades from conventional medical therapy, which mainly includes administration of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists, to biomedical engineering methods, which include interventional engineering, such as percutaneous balloon mitral valvotomy, percutaneous coronary intervention, catheter ablation, biventricular pacing or cardiac resynchronization therapy (CRT) and CRT-defibrillator use, and implantable cardioverter defibrillator use; mechanical engineering, such as left ventricular assistant device use, internal artery balloon counterpulsation, cardiac support device use, and total artificial heart implantation; surgical engineering, such as coronary artery bypass graft, valve replacement or repair of rheumatic or congenital heart diseases, and heart transplantation (HT); regenerate engineering, which includes gene therapy, stem cell transplantation, and tissue engineering; and rehabilitating engineering, which includes exercise training, low-salt diet, nursing, psychological interventions, health education, and external counterpulsation/enhanced external counterpulsation in the outpatient department. These biomedical engineering therapies have greatly improved the symptoms of CHF and life expectancy. To date, pharmacotherapy, which is based on evidence-based medicine, large-scale, multi-center, randomized controlled clinical trials, is still a major treatment option for CHF; the current interventional and mechanical device engineering treatment for advanced CHF is not enough owing to its individual status. In place of HT or the use of a total artificial heart, stem cell technology and gene therapy in regenerate engineering for CHF are very promising. However, each therapy has its advantages and disadvantages, and it is currently possible to select better therapeutic strategies for patients with CHF according to cost-efficacy analyses of these therapies. Taken together, we think that a new era of biomedical engineering for CHF has begun. Keywords: Chronic heart failure, Biomedical engineering, Treatment
format	article
author	Chun-Song Hu Qing-Hua Wu Da-Yi Hu Tengiz Tkebuchava
author_facet	Chun-Song Hu Qing-Hua Wu Da-Yi Hu Tengiz Tkebuchava
author_sort	Chun-Song Hu
title	Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
title_short	Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
title_full	Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
title_fullStr	Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
title_full_unstemmed	Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
title_sort	treatment of chronic heart failure in the 21st century: a new era of biomedical engineering has come
publisher	KeAi Communications Co., Ltd.
publishDate	2019
url	https://doaj.org/article/02fb3e512c8c4901bce4e4f36630c152
work_keys_str_mv	AT chunsonghu treatmentofchronicheartfailureinthe21stcenturyaneweraofbiomedicalengineeringhascome AT qinghuawu treatmentofchronicheartfailureinthe21stcenturyaneweraofbiomedicalengineeringhascome AT dayihu treatmentofchronicheartfailureinthe21stcenturyaneweraofbiomedicalengineeringhascome AT tengiztkebuchava treatmentofchronicheartfailureinthe21stcenturyaneweraofbiomedicalengineeringhascome
_version_	1718394670784970752

Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

Ejemplares similares